Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InoviqASX:IIQ 27 Return-on-Tangible-Equity is -71.63% as of Dec. 2025. GuruFocus rates ASX:IIQ with a GF Score™ of 27/100 and a GF Value™ of A$0.51 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Inoviq ranks worse than 78.13% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Inoviq's annualized net income for the quarter that ended in Dec. 2025 was A$-7.92 Mil. Inoviq's average shareholder tangible equity for the quarter that ended in Dec. 2025 was A$11.05 Mil. Therefore, Inoviq's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -71.63%.
The historical rank and industry rank for Inoviq's Return-on-Tangible-Equity or its related term are showing as below:
ASX:IIQ'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1009.3 Med: -75.68 Max: -41.55
Current: -67.03
During the past 13 years, Inoviq's highest Return-on-Tangible-Equity was -41.55%. The lowest was -1,009.30%. And the median was -75.68%.
ASX:IIQ's Return-on-Tangible-Equity is ranked worse than 78.13% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.605
vs ASX:IIQ: -67.03
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Inoviq Return-on-Tangible-Equity Related Terms
Inoviq Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Inoviq's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IIQ vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Inoviq's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inoviq Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inoviq's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Inoviq's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -71.63% mean?
Inoviq (ASX:IIQ) has a Return-on-Tangible-Equity of -71.63% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Inoviq and its competitors. According to the industry distribution chart, Inoviq ranks #150 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 78.1%.
Is Inoviq's Return-on-Tangible-Equity too high?
Inoviq's current Return-on-Tangible-Equity is -71.63%. Based on the distribution chart, Inoviq ranks #150 out of 192 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Inoviq has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inoviq's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Inoviq ranks #150 out of 192 companies for Return-on-Tangible-Equity. This places Inoviq in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Inoviq and its competitors. Inoviq's current Return-on-Tangible-Equity is -71.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inoviq stock overvalued right now?
Based on GuruFocus' analysis, Inoviq (ASX:IIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.51, compared to a current price of A$0.20 — trading 60.8% below its estimated fair value. The current Return-on-Tangible-Equity is -71.63%. Inoviq's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Inoviq (ASX:IIQ), the current Return-on-Tangible-Equity is -71.63% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inoviq (ASX:IIQ) Overvalued in 2026?
Based on GuruFocus' analysis, Inoviq stock appears to be undervalued.
The current stock price of A$0.20 is trading 60.8% below its estimated GF Value™ of A$0.51.
GuruFocus considers Inoviq to be Possible Value Trap.
Key valuation signals for ASX:IIQ:
Return-on-Tangible-Equity: -71.63%
GF Value™: A$0.51 vs. price of A$0.20 (60.8% below fair value)
No single metric tells the full story. See the ASX:IIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.
27GF Score
Get the complete analysis for ASX:IIQ
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IIQ has been successfully added to your 
